Commercial StrategyPlans are in place to launch anito-cel in 160+ treatment centers, indicating a strong commercial strategy.
Efficacy And CompetitionThe 18-month landmark progression-free survival (PFS) with anito-cel shows favorable comparison to BCMA CAR-T cilta-cel, highlighting its competitiveness.
Safety ProfileAnito-cel is clearly differentiated on toxicity, with zero observations of parkinsonism, cranial nerve palsy, and enterocolitis events.